Gilead Sciences, Inc. (GILD): Gilead Sciences +3% AH on strong leukemia drug ... Seeking Alpha ... not fit for chemotherapy will be stopped early based on an analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving the drug plus rituximab compared to those receiving ... |
